Lot B7325 is one of 8 lots of Liraglutide we have release-tested for this catalogue, scored on purity, quantity, and batch traceability. Independent third-party HPLC/MS verification of this lot is available on request.
9.8/10
A+ Excellent
Purity
3.8 / 4
Quantity
4.0 / 4
Identifier
2.0 / 2
The test score is calculated from purity (how much of the vial content is the expected compound, with values closest to 100% best and below 98% considered unacceptable), quantity (how close the measured amount is to the label claim, more than plus or minus 20% is unacceptable), and identifier (whether the batch this vial came from can be traced to a certificate).
Sample details
ProductLiraglutide 5mg
Sample typeSealed retail vial
Date received31 Mar 2026
Physical detailsPrinted label / aluminium crimp / amber cap
Test details
MethodRP-HPLC-UV + LC-MS
Tested on02 Apr 2026
Tested byRTT Peptides QC
ReportQC-26700
Score breakdown
Purity
99.78%
3.8 / 4
Measured purity by RP-HPLC-UV against the ≥ 98.0% release specification. Net peptide content 95.1%.
Quantity
5.0mg
4.0 / 4
Label claim 5mg, measured 5.0mg, divergence 0.0%. Within plus or minus 5% of label scores full marks.
Identifier
B7325
2.0 / 2
Batch identifier printed on the vial and traceable to this certificate, so the lot can be verified end to end.
Analytical release certificate · RP-HPLC-UV with LC-MS confirmation Independent third-party verification available on request.
ReportQC-26700Issued2026-04-03Page1 of 1
Certificate of Analysis
Liraglutide · Lot B7325
SampleLiraglutide
Issued forRTT Peptides
Lot / BatchB7325
Label claim5mg
CASN/A
AppearanceWhite lyophilised powder
Date received2026-03-31
Date analysed2026-04-02
01 Purity by RP-HPLC-UV
Figure 1 · Reverse-phase HPLC-UV chromatogram at 214 nm. C18, 2.7 µm; gradient 0.1% TFA in water / acetonitrile at 1.0 mL/min.
Purity by RP-HPLC-UV: component retention time, peak area, and area percent
#
Component
RT (min)
Area (mAU·s)
Area %
1
RRT 0.33
2.96
4.6
0.11
2
Liraglutide ▸ main
9.00
4190.8
99.78
3
RRT 1.51
13.62
4.6
0.11
✓
Purity (HPLC) 99.78% · net peptide content 95.1% · meets the ≥ 98.0% release specification.
02 Identity by LC-MS
Expected average massper structure
Observed massconsistent
✓
Identity confirmed · observed mass conforms to the expected structure of Liraglutide.
03 Summary of results
Summary of results: test, method, specification, result, and outcome
Test
Method
Specification
Result
Outcome
Purity
RP-HPLC-UV, 214 nm
≥ 98.0 %
99.78 %
✓ Pass
Identity
LC-MS (ESI+)
Consistent with structure
Confirmed
✓ Pass
Net peptide content
By difference
Report
95.1 %
n/a
Appearance
Visual
White lyophilised powder
Conforms
✓ Pass
Reconstitution
Bacteriostatic water
Clear, particulate-free
Conforms
✓ Pass
The submitted lot conforms to identity and meets the stated purity specification. Analysis was performed by RP-HPLC-UV with LC-MS confirmation. Results relate only to the lot as received and tested and do not constitute a certificate of any third party.
Quality Assurance · RTT Peptides
Issued under the RTT Peptides quality programme; this is the vendor's own release certificate. Independent third-party HPLC/MS verification of any lot is available on request. Products are supplied strictly as research reagents for in-vitro laboratory use only, not for human or animal consumption. Report QC-26700 · RP.
This is the vendor's own release certificate. Independent third-party HPLC/MS verification of this lot is available on request.
Research use only
RTT Peptides sells laboratory research reagents. They are not for human or animal consumption. Please confirm before entering.
